Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...
Metsera, Inc.: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...
Sequim Gazette on MSN16h
Athletes break in new track at first meet
But now there’s more freedom to run.” It’s been nearly four years since Sequim athletes could host a track meet or hold ...
Southern Maryland News Online12h
SMAC male athletes earn region, state titles this winter
Throughout the winter on the hardwood, the indoor track and in the pool, a bevy of male athletes from across the Southern ...